- The Myeloma Beacon - https://myelomabeacon.org -
Genasense (oblimersen, G3139)
By: Admin; Published: October 15, 2008 @ 8:00 am | Comments Disabled
Brand Name: | Genasense |
Generic Name: | oblimersen |
Code Name: | G3139 |
Company: | Genta, Inc. & Aventis |
FDA Clinical Phase: | 3 |
Description:
Genasense is a type of antisense oligodeoxyribonucleotide. It may kill cancer cells by blocking the production of a protein that makes cancer cells live longer and by making them more sensitive to anticancer drugs.
Clinical Trials:
For a list of clinical trials studying Genasense for the treatment of multiple myeloma, see ClinicalTrials.gov [1].
Official website for Genasense: http://www.genta.com/genasense/ [2]
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/resources/2008/10/15/genasense/
URLs in this post:
[1] ClinicalTrials.gov: http://www.clinicaltrial.gov/ct2/results?term=&recr=&rslt=&type=&cond=multiple+myeloma&intr=Genasense&outc=&lead=&spons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=
[2] http://www.genta.com/genasense/: http://www.genta.com/genasense/
[3] http://www.cancer.gov/templates/db_alpha.aspx?searchTxt=Genasense: http://www.cancer.gov/templates/db_alpha.aspx?searchTxt=Genasense
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.